Mice and rats are the most common species used as experimental model systems for analyzing physiological traits, for investigating the pathogenesis of human diseases and for developing new therapies. Both species offer unique advantages for use in biomedical research, such as their versatility and the abundance of available resources, including mutant archives produced by the large-scale N′-ethyl-N′-nitrosourea (ENU) mutagenesis screens, the International Knockout Mouse Consortium (IKMC), the International Gene Trap Consortium (IGTC) and the European Mouse Mutant Archive (EMMA) [1] [2] [3] [4] [5] [6] . A large number of inbred strains have been successfully generated for mice and rats; these genetically standardized and phenotypically characterized strains are valuable and well-documented tools available for the scientific community. The availability of the full genome sequence of both the mouse and the rat further strengthened their positions as leading mammalian model organisms 7, 8 . A comprehensive comparison with the previously decoded human genome revealed a high similarity in the genomic sequences, presumably reflecting similarities in gene function between humans and rodents 9 .
The Norway rat (Rattus norvegicus) was the first mammal domesticated for scientific research 10 . Laboratory rats are widely used in pharmacological and toxicological testing, as well as in basic research for modeling the physiological processes of human organ systems. The rat's larger size and often closer similarity to human biology would seem to make the rat a better experimental tool than the mouse (Mus musculus). However, despite the many advantages of rats as model organisms, the laboratory mouse is currently the predominant mammalian species in biomedical research. This is mainly because of the availability of several genetic modification technologies developed and continuously advanced in mice over the past 30 years, which enabled gene trapping and the introduction of targeted mutations [11] [12] [13] [14] [15] .
Mutagenesis is currently the most frequently used method to examine gene function and regulation, and several strategies have been developed to experimentally induce mutations into rodent germlines. Mutagenesis by homologous recombination for producing knockout and knock-in animals was limited to mouse models because of the successful isolation and culture of pluripotent embryonic stem cells (ESCs). After more than two decades of intensive effort, pluripotent rat ESC lines have been successfully isolated and cultured 13, 16 . The application of the 2i cell culture system developed for mouse ESCs has further improved the derivation of rat ESCs 17, 18 , and, for the first time, it has enabled the generation of a targeted mutation in the rat genome by homologous recombination 19 . However, the use of ESCs to modify the rat genome is still very challenging. Therefore, in addition to the common technologies for genetic engineering, new strategies for manipulating the mouse and the rat genome have been recently developed. New tools for targeted mutagenesis that not only can be applied in ESCs but also are efficient enough for genome engineering directly in living embryos include zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system [20] [21] [22] [23] [24] [25] [26] .
Germline transgenesis in rodents
Germline transgenesis is an important procedure for the generation of heritable, loss-of-function or gain-of-function phenotypes in model species for investigations into the functions of biological pathways, as well as for animal biotechnology. Since 1981, the most routinely applied method in mice has been pronuclear DNA injection 27 . This methodology has also been adapted to rats and is performed in a very similar way 28, 29 . For mice, pronuclear injection of transgenes often yields more than 20% founders among the live offspring 27, 30 . In rats, the reported Germline transgenesis in rodents by pronuclear microinjection of Sleeping Beauty transposons efficiency of classical microinjection is much lower than that in mice, possibly owing to the substantially lower percentage of ova surviving the microinjection procedure 28, 31, 32 . Standard pronuclear injection of a transgene involves the introduction of a small number of identical copies of a linearized DNA molecule into a freshly fertilized oocyte. Linearization of transgene constructs is important because the integration frequency is much higher for linearized DNA molecules than it is for circular DNA molecules 33 . However, linearized molecules recombine with each other immediately after pronuclear injection and before chromosomal integration to form concatemers 34 . Consequently, the gene copy number per transgenic locus is unpredictable and unique for each founder line. In addition, transgenic concatemers can persist in a nonintegrated form for several cell divisions, resulting in unequal transgene distribution between the blastomeres of the early embryo 35 . Therefore, high percentages of the transgenic founders produced by pronuclear injection are genetic mosaics 36 . A further limitation associated with this technology is that multicopy concatemers are prone to undergo transcriptional silencing 37 , thereby compromising the production of transgenic stocks with reliable spatiotemporal patterns of transgene expression. In addition, integration of pronuclear injected transgenes often causes severe chromosomal alterations at the chromosomal integration site(s), including deletions, duplications and translocations [38] [39] [40] .
Another alternative approach to producing transgenic rodents is sperm-mediated gene transfer (SMGT) combined with intracytoplasmic sperm injection (ICSI) [41] [42] [43] . In this procedure, spermatozoa are subjected to disruption of their head membranes, hence the need for the sophisticated ICSI for fertilization. The resulting frequency of founders produced by this technique is comparable with standard pronuclear injections. An improved efficiency of SMGT was demonstrated for large constructs cloned in yeast artificial chromosomes (YACs) 44 . Furthermore, founders produced by SMGT are only rarely genetic mosaics 44 . However, there are major concerns regarding the effect of the procedure on the genetic material of the sperm and, consequently, on the genome of the resulting transgenic animal 45, 46 .
Higher transgenic rates were reported by injecting recombinant lentiviral vectors into the perivitelline space of ova in various animal models, including rodents and certain livestock species 47, 48 . The use of lentiviral vectors for transgenesis has been optimized in rats and resulted in a 22% average frequency of producing founders. Although this frequency certainly represents an improvement over classic pronuclear microinjection of naked DNA, it is much lower than the reported frequency of 80% in mice 47, 49 . Several problems with the use of lentiviral vectors remain, such as genetic mosaicism due to vector integration into the genome in later developmental stages, limitations of transgene size, vector-related toxicity, transcriptional silencing of proviral insertions by cellular mechanisms and preferential insertion into endogenous genes.
Thus, methods with the capacity to yield more robust germline transmission rates in addition to predictable transgene expression patterns, technical ease and greater safety would markedly improve transgenic studies in mammalian models.
Transgenesis with the Sleeping Beauty transposon
Similarly to retroviruses, DNA transposons integrate into the chromosomes of the host cells, a feature that forms the basis of their use for gene delivery. In nature, these elements contain a gene encoding a transposase enzyme flanked by inverted terminal repeats (ITRs) that carry binding sites for the transposase. Under laboratory conditions, transposons are applied as bicomponent vector systems, in which a DNA sequence of interest can be cloned between the transposon ITRs and mobilized by providing the transposase enzyme in trans, as an expression plasmid or as in vitro-synthesized mRNA (Fig. 1a) . During transposition, the transposase excises the genetic element from its donor plasmid and integrates it into a chromosomal locus (Fig. 1b) . On the basis of the fossil record of transposons that were active >10 million years ago in diverse fish species, an ancient transposon was 'awakened' (molecularly reconstructed) and named Sleeping Beauty (SB) after the Grimm brothers' fairy tale 50 . SB was the first transposon that was shown to be capable of efficient transposition in vertebrate cells, thereby opening new avenues for genetic engineering in animal models (reviewed in ref. 51 ).
The SB system combines the advantages of retroviral vectors (permanent gene insertion into recipient genomes) with those of naked DNA molecules (simple and safe production and application). As transposition is a cut-and-paste mechanism that does not involve reverse transcription, transposon-based vectors can tolerate larger and more complex transgenes. The SB system is not strictly limited by the size of expression cassettes 52 . Indeed, inserts as large as bacterial artificial chromosomes (BAC) were recently shown to transpose with SB at reasonable efficiencies in mouse ESCs 53 . When performing transgenesis, a single-copy transgene insertion that does not disturb endogenous gene functions is desirable. Chromosomal integration of SB transposons is nearly random at the genome level, resulting in ~60% of the SB transposon integrations being intergenic [54] [55] [56] [57] As the transposase is only transiently present in the cell, the integrated transposon is stable (i.e., it will not undergo further rounds of transposition), thereby rendering transposons easily controllable, conditional DNA-delivery tools that can be used for versatile applications, including germline gene transfer. We have recently developed a hyperactive variant of the SB transposase, called SB100X, by in vitro evolution 60 . SB100X supports efficient germline transgenesis in mice 60, 61 , rats 61 , rabbits 61, 62 and pigs 63, 64 . We optimized the SB100X-mediated protocol by carefully titrating the relative amounts of transposase and transposon to obtain optimal rates of transgenesis to generate founders, and extensively evaluated it for efficacy, toxicity, mosaicism, germline transmission, insertion site preferences, transgene copy number and silencing. Genotyping of numerous transgenic lines produced by SB transposition demonstrated single-copy integrations of the transposon as expected from the cut-and-paste integration reaction catalyzed by the SB transposase 61 . The numbers of integrations per genome were shown to be dependent on and hence controllable by the concentration of both components of the transposon system in the injection cocktail. The best results in terms of the frequency of founder animals with mostly single integrations were achieved by a reduction of the amount of transposon plasmid DNA 61 .
One of the most important aspects of using this protocol is that no major mosaicism was observed, and transgene expression was maintained for several generations in all species tested. The lack of mosaicism is in sharp contrast to any other current nonviral or viral approaches to transgenesis. This is likely due to the very nature of transgene integration: transposition results in precise (the ends of the integrating DNA are well defined) genomic integration of monomeric transgene units within a short time frame after administration, thereby minimizing mosaicism. Furthermore, unlike retroviral vectors 48, [65] [66] [67] , SB100X-catalyzed transgene integration does not seem to trigger transcriptional silencing 56, 61 . Therefore, the application of the SB transposon system described here will markedly enhance the mouse and rat genomic toolbox.
Limitations
DNA transposons, including SB, are regulated by overproduction inhibition, which means that overexpression of the transposase has a negative effect on transposition 56, 68 . The practical consequence of this phenomenon is that an optimal ratio of transposon donor plasmid to transposase mRNA needs to be established. As a rule of thumb, the injection mixture should contain 5 ng/µl SB100X mRNA and 0.4 ng/µl transposon donor plasmid for an SB vector of a total size of ~6.1 kb and containing a ~2.5-kb transgene cassette 60 . For larger transgenes, the concentration of the donor plasmid in the microinjection mixture must be increased to maintain optimal molar ratios between the transposon and the transposase. It has been found that embryos tolerate concentrations of transposon donor plasmid of up to 2 ng/µl in mice 60 .
Experimental design
The generation of transgenic rodents by SB-mediated transgenesis is achieved through microinjection of a plasmid carrying a gene of interest, cloned between the ITRs of SB, and synthetic transposase mRNA (Fig. 1) into the pronucleus of a fertilized oocyte, with frequencies of transgenic founders of 50-70% for both mice and rats 61 . The protocol consists of the following major steps. (Steps 1-26) . These steps include molecular cloning of a gene of interest into SB transposon vectors and purifying the resulting plasmid construct, preparing mRNA encoding the transposase by in vitro transcription, and preparing a nucleic acid mixture consisting of the purified transposon plasmid carrying the ITRflanked transgene and the transposase mRNA.
Preparation of SB transposon components for microinjection

Transgenesis with SB in mice (Steps 27-39) and rats (Steps 40-74).
These steps include preparing donor mice, collecting ova, microinjecting the nucleic acid mixture into the ova and transferring the microinjected ova into surrogate mothers.
Genotyping of transgenic animals (Steps 75-100).
These steps include a PCR-based analysis of the F 0 as well as F 1 offspring to establish founders and germline transmission. A simple, quick PCR test can be applied to determine the presence of integrated transposon sequences from genomic DNA samples. The PCR primers amplify sequences in the left ITR of SB; thus, this protocol can be universally applied irrespective of the gene of interest that was cloned in the SB vector. To assess copy numbers of integrated transposons and to map the genomic integration sites, a ligation-mediated PCR procedure is applied 69 . The procedure consists of a restriction enzyme digest of the genomic DNA, ligation of an oligonucleotide adaptor to the ends of the fragmented DNA, PCR amplification of a transgene or genomic DNA junction in two rounds of PCR with primers specific to the adaptor and to the ITRs of the SB transposon, and sequencing of the junctions to map the insertion to the reference genome 70 . Finally, a locus-specific PCR is applied to distinguish and track the individual integrations in the F 1 and later generations.
MaterIals
REAGENTS Animals
Two different strains are required, the donor strain to produce ova and the recipient strain, which is used to provide pseudopregnant surrogate mothers. Donors: predominantly used inbred strains are C57BL/6 mice and F344 rats Surrogate mothers and sterile males: recipients of embryos are usually outbred owing to their superior fertility. Examples of preferred strains are NMRI and ICR mice at an age of [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 
REAGENT SETUP Preparation of the transposase mRNA Synthetic mRNA encoding the SB100X transposase can be produced (Step 17) from either the pCMV(CAT)T7-SB100X or the pcGlobin2-SB100X plasmids 60 (see Reagents). The latter vector supports in vitro synthesis of SB100X mRNA containing zebrafish β-globin 5′-and 3′-UTRs and a 30-mer synthetic poly(A) sequence from a T7 promoter 71 . DEPC treatment of water Add 1 ml of DEPC to 1 liter of Milli-Q water to make a 0.1% (vol/vol) solution; shake it vigorously. Continuously stir the solution for 12 h at room temperature (~20 °C). Autoclave it for 1 h to remove any trace amount of DEPC, as residual DEPC reacts with purine residues in RNA. DEPC-treated water can be stored indefinitely at room temperature. NaCl solution for oligonucleotide annealing To prepare a 500 mM stock solution, dissolve 29. 
EQUIPMENT SETUP Chambers for microinjection
The chamber is made from a microscope slide with a 15-mm hole drilled in its center; the slide is then glued to a cover glass that forms the bottom of the chamber. Store the chamber in a Petri dish (diameter 100 mm) and sterilize it by UV irradiation before use. Alternatively, use heat-sterilized concave ground microscope slides. Injection and holding capillaries Both injection and holding capillaries are commercially available. However, if transgenic animals are routinely generated in a laboratory, it is recommended to produce your own capillaries by using a puller and a microforge. The specific pulling conditions depend on the glass tubes and on the specific puller equipment used. Store the GD-1 glass tubes and the pulled injection capillaries (with filaments) in a way that avoids dust accumulation. The finely drawn injection capillary should have an outer diameter at the tip of ~1 µm. If the tip is sealed, push it slightly on the holding capillary to break the tip open. Alternatively, it can be opened before loading the injection solution by submersing the very tip of the capillary into 20% (vol/vol) hydrofluoric acid for 8-12 s. Stop the reaction by washing the tip in sulfuric acid for 2-3 s, followed by washing in water (biotechnology performance certified) for 2-3 s, and then in pure ethanol for 2-3 s. Optionally, silicon-coat the injection capillary (Sigmacote for 5-7 s) and wash it in water (biotechnology performance certified) for 2-3 s. Bend the tips of the injection and the holding capillaries (2-3 mm long) to an angle of 15° (with a microforge). Flame-polish the opposite ends of the injection and the holding capillaries over the flame of the burner (for the smooth insertion of capillaries into the microinstrument holders).
The holding capillaries are pulled with specific pulling conditions from glass tubes without filament (G-1, G-100). Use a microforge to break the pulled glass at an outer diameter of ~70 µm and fire-polish the tip to an inner diameter of ~15-30 µm. If necessary, heat-sterilize both capillaries at 200 °C for 2 h.  crItIcal The selection of optimal injection micropipettes markedly affects the speed of DNA injection, the survival rate of injected ova and the degree of control of pronuclear injection. Hand-operated manipulation and transfer capillaries Hand-pull transfer and manipulation capillaries are obtained from borosilicate glass tubes heated over the flame of a burner. Use a glass cutter to score the pulled segment at an internal diameter of ~300 µm (manipulation capillary) and 100 µm (transfer capillary) (diameters are measured by using the scale of a stereomicroscope), then break and fire-polish the end. This must be done very quickly in order to avoid sealing the tip. If necessary, sterilize the capillaries by heat or UV irradiation before use. Transfer capillaries can be used by mouth-controlled or hand-controlled pipetting. For the latter, connect the prepared capillary with rubber tubing (length 1.5-2 cm, closed with a knot on one end) that fits to the diameter of the pipette barrels.  crItIcal The selection of optimal transfer capillaries enables fast, precise and effective manipulation of embryos without any damage or loss throughout the entire procedure. proceDure preparation of rnase-free transposon (Itr-flanked transgene) donor plasmid • tIMInG 2-4 h  crItIcal At every step of the protocol, use RNase-free plasticware and wear gloves while handling the reagents and samples to prevent RNase contamination. 1| Clone your gene of interest between the ITRs of an SB transposon donor plasmid by standard molecular cloning procedures (http://www.protocol-online.org).
2|
Transfer at least 5 µg of transposon donor plasmid in 400 µl TE buffer into a 1.5-ml tube, and then add 400 µl of phenol/chloroform/isoamyl alcohol to the tube. ! cautIon This is a hazardous chemical. Avoid contact with skin, eyes and airways.
3| Vortex the tube for 15 s and leave it on the bench for 2 min. Repeat this step three times to completely inactivate the residual RNase.
4|
Centrifuge the tube at 12,000g for 5 min at room temperature.
5|
Transfer the top layer to a new, RNase-free 1.5-ml tube and add 400 µl of chloroform/isoamyl alcohol. ! cautIon This is a hazardous chemical. Avoid contact with skin, eyes and airways.
6| Vortex the tube for 15 s and centrifuge it at 12,000g for 5 min at room temperature.
7|
Transfer the aqueous top layer, containing the DNA, to a new, RNase-free 1.5-ml tube, add a one-tenth volume of 3 M sodium acetate and 2.5 volumes of ethanol, and then precipitate the DNA for 30 min at −20 °C.
8|
Spin the tube down at 12,000g for 15 min at 4 °C and discard the supernatant.
9|
Wash the pellet in cold 70% (vol/vol) ethanol (RNase-free) by keeping the ethanol on the pellet for 10 min, centrifuging it at 12,000g for 1 min at 4 °C and then discarding the supernatant. Repeat this step to completely remove any residual chemicals that may not be tolerated by the embryos.  crItIcal step DEPC is not tolerated by the embryos and the RNase-free solutions that come in contact with the injected material should be purified by filtration. Therefore, use the filtered, RNase-free water for the preparation of 70% (vol/vol) ethanol.
10| Air-dry the pellet for 5-10 min and resuspend it in 100 µl of EmbryoMax injection buffer.
11|
Measure the concentration of the plasmid DNA with a NanoDrop spectrophotometer. 
15|
Prepare the digested plasmid RNase-free by phenol/chloroform extraction as described in Steps 2-10. In Steps 2 and 5, set the volumes of the digested plasmid DNA, the phenol/chloroform/isoamyl alcohol and the chloroform/isoamyl alcohol to 100 µl each. This will decrease the liquid volume during precipitation and improve DNA recovery.
16|
Measure the concentration of the linearized plasmid DNA with a NanoDrop spectrophotometer.
17|
Synthesize the mRNA by using the mMessage mMachine T7 kit according to the manufacturer's instructions.
18|
After mRNA synthesis, perform the Turbo DNase treatment and phenol/chloroform extraction as suggested in the kit manual, with the added modification of washing the pellet twice in cold 70% (vol/vol) ethanol after the isopropanol precipitation after the phenol/chloroform extraction. Use filtered, RNase-free water for the preparation of 70% (vol/vol) ethanol. Air-dry the pellet for 5-10 min.
19|
Resuspend the mRNA in 20 µl of filtered, RNase-free water.
20|
Measure the concentration of the in vitro-synthesized mRNA with a NanoDrop spectrophotometer. The typical yield is ~1 µg/µl.
21|
Prepare a 1% (wt/vol) agarose gel with nuclease-free TBE buffer, Milli-Q water treated with DEPC and agarose powder. ! cautIon DEPC is a hazardous chemical. Avoid contact with skin, eyes and airways.
22| Load 1 µl of the in vitro-synthesized mRNA (Step 19) in an RNA loading buffer (supplied with the mMessage mMachine T7 kit) and a DNA size marker and run the gel. The SB100X mRNA prepared using the T7 promoter on the ClaI-digested pcGlobin2-SB100X runs on a normal agarose gel between 700 and 800 bp (Fig. 2, lane 1) . Typically, the in vitro-synthesized mRNA runs as one band on a nondenaturing gel (Fig. 2, lane 1) . Alternatively, two bands may be visible (Fig. 2, lane 2 Mouse transgenesis: preparation of the ovum donors • tIMInG 3 d  crItIcal Mouse transgenesis is described in Steps 27-39.  crItIcal The staff of a transgenic lab and animal facility need to have substantial experience in reproductive biology, methods of assisted reproduction, cell culture techniques, mouse genetics and molecular biology.  crItIcal The animals need to be maintained and treated under conditions that are suitable in terms of hygienic quality. The use of healthy animals in SPF (specific pathogen-free) or SOPF (specific opportunistic pathogen-free) conditions assures the best results with regard to efficacy of the method, and it allows for the possibility of unrestricted distribution of the resulting founders to other facilities.  crItIcal The donor strain must be selected according to the appropriate genetic background for the transgene and the ability for efficient superovulation. Inbred strains are preferred because they have a defined genetic background. However, they are generally less efficient in all crucial aspects of production of ova, microinjection and embryonic development than outbred or hybrid animals. 27| Apply hormonal treatment to increase the number of ova per donor. Superovulate mice between 9:00 and 10:00 by an i.p. application of 5 IU of PMSG, and then 46-48 h later (directly before mating) with an injection of 5 IU of hCG (Fig. 3) . ? trouBlesHootInG 
28|
Pair the mice for mating. Put the females into the male's cage for mating and not vice versa. Putting males in a new cage may induce exploration behavior and delay the start of copulation. The optimal dosage of both hormones can vary depending on the mouse strain used and the age of the animals.  crItIcal step The most appropriate age of donors of different genetic backgrounds needs to be empirically determined. For example, F 1 -hybrid and BALB/c females are used as donors as young adults at ~7 weeks of age. In contrast, the superovulation of C57BL/6 females is most efficient in juveniles during their prepubescent stage of development.
Isolation of ova • tIMInG 1 h 29|
Equilibrate the M16 medium in the incubator (at 37 °C, 5% CO 2 ) for ~12 h before use. Prewarm M2 medium, mineral oil, glass slides and diluted hyaluronidase solution on a warming plate (37 °C) before use. Prewarm the injection anesthetics, analgesics and eye ointment to room temperature.
30|
In the morning of the day intended for embryo transfer to the recipient mice, ~23 h after hCG application and mating, collect the ova from the dissected oviducts of donor mice by flushing them with M2 medium (Fig. 3a) . At this time, the ova are still in or partly released from the cumulus complex and both pronuclei are clearly visible. ? trouBlesHootInG
31|
Remove the remaining sticky cumulus cells of the flushed ova by incubation in 1 mg/ml hyaluronidase solution for 3-5 min in a Petri dish. Examine the size of the pronuclei under the microscope, and store the ova in M2 medium on a warming plate until the pronuclei are of the appropriate size for injection (~15 µm in diameter) (Step 34). The optimal time window for the pronucleus injection lasts for ~3 h from when the male pronucleus reaches 15 µm in diameter to shortly before the disappearance of the fully developed pronuclei. The diameter of the pronucleus can be estimated by comparing it with the diameter of the ova (which is ~80 µm). We recommend the implementation of all steps of ova preparation in a laminar flow bench with a 37 °C heated surface.  crItIcal step Dissect the oviduct and flush the ova in cumulus complexes immediately after euthanizing the donor female. Avoid changes of osmolarity due to evaporation of the medium during culture or injection, as the resulting shrinking of the ova will complicate microinjection.
Microinjection of ova • tIMInG 2-3 h
 crItIcal RNA is very unstable and sensitive to ribonucleases. Use gloves during all steps of handling the injection cocktail. All materials, including pipette tips, injection buffer, reaction tube, DNA preparations and injection capillaries, must be clean and free of ribonucleases. 32| Place ~30 ova into the upper part of a small drop of M2 medium in the injection chamber (see Equipment Setup), covered by pre-warmed mineral oil.
33|
Keep the transposon DNA/transposase mRNA-injection mixture from Step 26 at 4 °C during use. Fill the injection capillary with ~1 µl of injection mixture by using a microloader or by inverting the capillary into the injection buffer and allowing it to fill up by capillary action. Ensure that the tip of the injection capillary is open.  crItIcal step Ova are not adherent to the surface of the slide and therefore need to be fixed by a holding capillary for injection.
34|
By using an inverted microscope and a micromanipulator, select the paternal pronucleus on the basis of its larger size, and fix the ovum with the holding capillary in such a way that the pronucleus is located near the horizontal axis of the ovum (Fig. 4) . Insert the injection capillary into the pronucleus and inject until the pronucleus visibly swells (~1-2 pl). The diameter of the pronucleus will increase from ~15 µm to 20 µm. As the plasma membrane of a mouse ovum is extremely elastic, penetration usually does not occur until the tip of the injection capillary is inside the pronucleus. ? trouBlesHootInG 35| Move each ovum after successful microinjection into the lower part of the oil-covered M2 drop until all ova are treated.  crItIcal step Further details about pronuclear injection can be found in refs. 72,73. ? trouBlesHootInG preparation of surrogate mothers • tIMInG 1-3 d 36| Mate surrogate females monogamously or bigamously to vasectomized, sterile males of the same outbred stock (alternatively, mutant strains expressing male infertility and asthenozoospermia can be used if their mating behavior is proved to be normal and if they produce a vaginal plug) in the afternoon of the day before microinjection (Fig. 3a) , to produce recipients for the injected embryos on the next day. Avoid pairing mice too early (e.g., in the morning) because any female mouse that had undergone estrus on the previous night could immediately mate and may lose the vaginal plug by the next morning. As the presence of a vaginal plug is a marker of a successful mating, this could result in undetected pseudopregnant females.  crItIcal step Calculate the number of matings necessary to provide the required number of surrogate mothers. The estrous cycle of mice is ~4 d long, and therefore 25% of mated females are expected to have a vaginal plug. To increase the frequency of plugged females, they can be stimulated 48 h before mating by exposure to male pheromones (Whitten effect) 74 . This can be done with dirty bedding from the stud male's cage. embryo transfer • tIMInG 2 h 37| Identify pseudopregnant recipients by vaginal plug control on the morning after mating. As the microinjection is performed in the morning, injected ova can be retransplanted on the afternoon of the same day (Fig. 3a) . If not enough surrogate mothers are available, the remaining ova can be cultured overnight in equilibrated M16 medium in an incubator and retransplanted the next morning as two-cell stage embryos into 0.5-d post coitum (d.p.c.) pseudopregnant females. Use the instruments shown in Figure 5a for embryo transfer.
38|
Anesthetize the pseudopregnant female with 10 mg/100 g body weight of ketamine (Ketasol) and 0.4 mg/100 g body weight of xylazine (Xylasol) (Fig. 5b) . Other anesthesia protocols are possible depending on the availability of appropriate equipment (inhalation anesthesia) or on local regulations 75 .  crItIcal step Perform embryo transfer only after the animal has reached surgical tolerance under general anesthesia. Surgical tolerance is tested by the withdrawal reflex, after pinching the hind foot. To prevent hypothermia, place the animals on a warming plate during surgery and until recovery from the anesthesia. Cover the animals' eyes with eye ointment to protect them from drying.  crItIcal step Pseudopregnancy can be confirmed by the swollen ampulla. 
41|
Shave the lower abdomen with clippers and sterilize the shaved region with 70% (vol/vol) ethanol. With a pair of curved forceps and scissors, make a cut across the lower abdomen (the incision in the midline wall should be ~1 cm wide).
42| By using blunt forceps and scissors to separate the vas deferens from the surrounding tissue, gently grasp the vas deferens with the forceps, lift it out of the incision and cut off the section in the loop of the vas deferens.
43|
Return the vas deferens gently back inside the abdominal cavity, and repeat the procedure on the other side. Sew the incision in the body wall with separate stitches and close up the skin with three Michel clips.
44|
Keep rats in a warm place, and be sure to supervise and monitor them until they have recovered from anesthesia. Allow the males to recover for 2 weeks before using them for inducing pseudopregnant females.
superovulation of female donors • tIMInG 3 d 45|
To stimulate the ovum donors for microinjections, select a group of 6-8 female rats (40-90 d old) and inject them with an i.p. injection of 20 IU of PMSG (Sergon) in 0.4 ml of diluted gonadotropin (see Reagent Setup) between 9:00 and 10:00 (Fig. 3b) . 46| For ovulation and fertilization, inject the female rats with an i.p. injection of 25 IU of hCG (Pregnyl) in 0.5 ml of diluted gonadotropin (see Reagent Setup) 48-49 h after the Sergon injection (Fig. 3b) , and then transfer the injected rats individually into cages with a fertile male and mate them overnight.
47|
On the next morning, between 9:00 and 10:00, check female rats for vaginal plugs; mark the positive rats on the tail and place them into clean cages.  crItIcal step The day of plug observation is day 1 of pregnancy.
recovery and manipulation of fertilized ova • tIMInG 1 h per eight superovulated donors 48| Euthanize the superovulated (donor) females with detected vaginal plugs (Step 47) by cervical dislocation on day 1 of pregnancy, between 14:00 and 16:00 (Fig. 3b) . Sterilize each abdomen with 70% (vol/vol) ethanol and open the abdominal cavity with scissors.
49|
Hold the proximal part (~1 mm) of the uterine horn with forceps and dissect the oviduct with the help of fine scissors. Wash the oviduct in 300-400 µl of M2 medium (warmed to room temperature) and transfer it into a 100-µl drop of M2 medium placed on the lid of a 60-mm sterile tissue culture Petri dish (each oviduct in its individual drop of M2 medium, place four oviducts separately on one lid).
50|
Place two 200-µl drops with hyaluronidase solution beside each drop with oviducts, and then transfer the Petri dish lid with oviducts under a dissecting microscope. Fix the ampulla portion of the oviduct with one fine forceps and tear it open with the second fine forceps.
51|
Release cumulus complexes with ova, transfer them (with a wide manipulation capillary) into the drop with hyaluronidase and incubate cumulus complexes in this drop for 3-5 min (incubate all cumulus complexes from one donor in one drop with hyaluronidase).
52|
With the help of gentle pipetting (with a narrow manipulation capillary), free ova from the cumulus cells, wash them in fresh M2 medium and transfer all fertilized ova into 5-µl drops of M2 medium placed on the bottom of the injection chamber.
53|
Place the microinjection chamber with the ova under the inverted microscope (Olympus IX70, equipped with DIC optics, 10× eyepieces, 5×, 20× and 40× objectives). Record the number of fertilized ova showing two pronuclei and a second polar body.
54|
Place the injection chamber with the ova under the stereomicroscope, transfer a group of ova collected from a single donor from the M2 medium into a drop of CO 2 -preincubated G-IVF PLUS medium at room temperature, wash them by repeated pipetting in this drop and transfer them into a well (containing 300 µl of CO 2 -preincubated G-IVF PLUS medium) of a four-well plate.
55|
Keep the ova in the incubator in 6% CO 2 at 37 °C for 1-4 h until microinjection. Microinjection is done between 16:00 and 20:00 on day 1.
pronuclear injection • tIMInG 1-3 h per 100-200 ova 56| Place a 5-µl drop of M2 medium in the center of the microinjection chamber and cover the drop with mineral oil.
57|
For DNA microinjection, transfer a group of 25-30 fertilized ova from the four-well plate into a 300-µl drop of M2 medium, placed on the lid of a 60-mm Petri dish, and then wash them and place them in the M2 medium drop in the microinjection chamber.
58|
Mount the chamber with ova under the inverted microscope equipped for microinjection (Olympus IX70 with DIC optics, Narishige micromanipulators, FemtoJet injector and CellTram Air for operation of the holding microcapillary).
59|
Fill the injection capillary with 1 µl of injection mixture (Step 26) with the help of a microloader.
60|
Install the holding and injection capillaries into basic positions close to each other in the very center of the drop of M2 medium situated in the center of the chamber, with all ova in the lower half of the drop (carry out the installation at magnification 10× eyepieces and 5× objective).
61|
Fix a selected fertilized ovum showing distinct pronuclei and a second polar body to the holding capillary under the DIC optic (magnification 10× eyepieces and 20× objective), and microinject the ovum (Fig. 6a) so that the volume of the injected pronucleus visibly increases. Microinjection is done between 16:00 and 20:00; inject 100-200 ova per session (Fig. 3b) .  crItIcal step Injection capillaries are changed whenever the process of microinjection is out of order (clogged or broken tips, increased number of lysed ova, remnants of cytoplasm or pronuclear membranes on the surface of microinjection capillaries).
62|
Collect all injected ova in the upper half of the working field (Fig. 6a) , while the rest (unfertilized ova and all abnormal and degenerated ova) are left in the lower half of the field.
? trouBlesHootInG
In vitro culture of injected ova • tIMInG 15-20 h 63|
Transfer the injection chamber with injected ova under the stereomicroscope and collect all surviving injected ova with a manipulation capillary.
64|
Transfer and wash the ova in a drop of CO 2 -preincubated G-IVF PLUS medium at room temperature, and then place them into a well (containing 300 µl of CO 2 -preincubated G-IVF PLUS medium) of a four-well plate.
65|
Insert the four-well plates into the incubator in 6% CO 2 at 37 °C and keep the injected ova there for 15-20 h. 
67|
On the next morning, between 9:00 and 10:00, use only the rats showing vaginal plugs as foster mothers. Use them for embryo transfer on the same day as vaginal plugs are detected (between 10:00 and 11:00, Fig. 3b ).
embryo transfer into recipient foster mothers • tIMInG 1 h per eight recipient foster mothers  crItIcal Embryo transfer of injected two-cell embryos is done between 9:00 to 10:00 to avoid a two-cell block.
To reduce surgical trauma only a unilateral transfer into the oviduct is made. 68| Anesthetize recipient foster mother by i.p. injection of Narketan (150 mg/kg) and Xylapan (2 mg/kg), shave the abdomen (left flank, 4 × 2 cm), sterilize it with 70% (vol/vol) ethanol and open the abdominal cavity (cut into the skin and body wall, 1-2 cm).
69|
Pull out the abdominal fat with the ovary, oviduct and proximal part of the uterine horn, and then fix them on a strip (3 × 2 cm) of woven wound dressing soaked in saline so that the infundibulum is clearly visible.
70|
Place the stereomicroscope in the laminar flow box, make a hole in the ovarian bursa (with the help of two pairs of fine forceps and taking care to avoid bleeding) and fix the infundibulum on a fine strip of paper (2 × 5 mm) cut off from the paper towel. 71| Take the four-well plate with injected embryos from the incubator (Step 65), transfer it under the stereomicroscope placed inside the laminar flow box and select two-cell embryos for transfer into recipient foster mothers.
72|
Aspirate two-cell embryos into the manipulation capillary with a narrow opening; transfer 10-14 embryos to one recipient foster mother in a minimal volume of G-IVF PLUS medium, with each two-cell embryo placed between small air bubbles.
73|
Insert the manipulation capillary with two-cell embryos into the infundibulum (close to the first bend of the oviduct) and gently expel the medium with two-cell embryos into the oviduct.
74|
Gently place the abdominal fat with ovary, oviduct and uterine horn back into the abdominal cavity, close up the abdominal wall with a suture and close the skin with wound clips. Place the foster mother in a cage and keep her in a warm place for 1-2 h until she wakes up and is mobile.  crItIcal step Avoid exposing surrogate mothers to pheromones of an unfamiliar male for at least the first 4 d after embryo transfer. Exposure would have a drastic effect on the female's reproductive state; it might result in termination of the early pregnancy and the return of the estrous cycle (Bruce effect) 79 . (Fig. 4c and Fig. 6b-d (Fig. 7b) , each in 50-µl final volumes. Include a negative control sample (genomic DNA isolated from a nontransgenic animal) as well. Follow the instructions of the enzyme supplier. To reach complete digestion, incubate the reaction for 3 h at 37 °C.  crItIcal step Always use high-quality genomic DNA as a template for PCR. Good-quality genomic DNA runs on an agarose gel as a dominant, high-molecular-weight band (Fig. 7c) .
79| Add 50 µl of phenol/chloroform/isoamyl alcohol to each tube.
80|
Vortex each tube for 10 s and leave it on the bench for 2 min. Repeat this step three times.
81|
Centrifuge the samples at 12,000g for 5 min at room temperature.
82|
Transfer the top layer (~50 µl) to a new 1.5-ml tube and add 5 µl (one-tenth volume) of sodium acetate and 125 µl (2.5 volumes) of ethanol; shake it well and let the digested DNA precipitate for 30 min at −20 °C. 
88|
To check digestion, run 200 ng of each sample on a 1% (wt/vol) agarose gel. The digested samples should run as a smear centered between 0.5 and 1 kb in size (Fig. 7d) .  pause poInt The digested genomic DNA samples can be stored at − 20 °C for up to 1 year.
89|
Prepare the double-stranded linkers by mixing the Linker( + ) oligo with the Linker( − )BfaI or with the Linker( − )DpnII oligo (table 1) in separate tubes at a final concentration of 10 pmol/µl each in 100 µl of TE buffer containing 50 mM NaCl.
90|
Place the tubes containing the oligonucleotide solutions into a boiling water bath for 2 min, switch off the heating and leave the tubes in the bath overnight to allow a slow cool-down and hybridization of the two single-stranded oligonucleotides to form the double-stranded linker.  pause poInt The annealed double-stranded oligonucleotides can be stored at − 20 °C for up to 1 year.
91|
Ligate the BfaI linkers and the DpnII linkers to the corresponding BfaI-and DpnII-digested genomic DNA samples, respectively (Fig. 7b) . Set up the ligation reaction containing the components listed in the table below and incubate it overnight at 16 °C. 
antIcIpateD results
The frequency of transgenic founders when using SB transposon-mediated transgenesis is expected to be in the range of 50-70% of live births in mice and 14-65% in rats (Fig. 7) . We found that for efficient transposition of a transposon of ~3 kb in length, using the optimized concentration of 0.4 ng/µl of plasmid and 5 ng/µl of SB100X mRNA will result in a high frequency of founders with single integration sites. Depending on the size of the transposon, it may be necessary to modify these concentrations. The number of independent integration sites per genome (Fig. 8) can be more efficiently controlled by modifying the concentration of injected transposon donor plasmid than by modifying the concentration of transposase mRNA 61 . Lowering the concentration of transposon plasmid should lead to a decrease in multiple integrations.
Transposon insertions are expected to be randomly distributed in the genome, with most transgenes located in intergenic regions. Nearly all founders produced by SB100X transposition are expected to transmit the transgene to the next generation. Although some differences in transgene expression levels and patterns between the founder lines are expected, there is no substantial transgene silencing in the F 0 and F 1 generations. 
